Pre-emptive targeting of the epitope spreading cascade with genetically modified regulatory T cells during autoimmune demyelinating disease

被引:10
作者
Yin, L [1 ]
Yu, M [1 ]
Edling, AE [1 ]
Kawczak, JA [1 ]
Mathisen, PM [1 ]
Nanavati, T [1 ]
Johnson, JM [1 ]
Tuohy, VK [1 ]
机构
[1] Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA
关键词
D O I
10.4049/jimmunol.167.11.6105
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epitope spreading or endogenous self-priming has been implicated in mediating the progression of autoimmune disease. In the present study we created an immune-deviated, epitope spreading response in SWXJ mice after the onset of experimental autoimmune encephalomyelitis, a prototypic autoimmune animal model widely used in multiple sclerosis research. We established an immunoregulatory spreading repertoire by transferring T cells genetically modified to produce high levels of IL-10 in response to a dominant epitope spreading determinant. Installation of a Th2/Tr1-like spreading repertoire resulted in a marked and prolonged inhibition of disease progression and demyelination characterized by 1) bystander inhibition of the recall response to the priming immunogen, and 2) a Th1 --> Tr1 immune-deviated spreading response involving a shift in the source of IL-10 production from the transferred regulatory population to the host-derived, endogenously primed repertoire. Thus, our data provide a rationale for cell-based therapeutic intervention in multiple sclerosis by showing that pre-emptive targeting of the epitope spreading cascade with regulatory T cells effectively induces an immune-deviated spreading response capable of inhibiting ongoing inflammatory autoreactivity and disease progression.
引用
收藏
页码:6105 / 6112
页数:8
相关论文
共 39 条
[1]   Functional diversity of helper T lymphocytes [J].
Abbas, AK ;
Murphy, KM ;
Sher, A .
NATURE, 1996, 383 (6603) :787-793
[2]   High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire [J].
Anderson, AC ;
Nicholson, LB ;
Legge, KL ;
Turchin, V ;
Zaghouani, H ;
Kuchroo, VK .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (05) :761-770
[3]   Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].
Bielekova, B ;
Goodwin, B ;
Richert, N ;
Cortese, I ;
Kondo, T ;
Afshar, G ;
Gran, B ;
Eaton, J ;
Antel, J ;
Frank, JA ;
McFarland, HF ;
Martin, R .
NATURE MEDICINE, 2000, 6 (10) :1167-1175
[4]   RAPID PURIFICATION OF PROTEOLIPIDS FROM RAT-BRAIN SUB-CELLULAR FRACTIONS BY CHROMATOGRAPHY ON A LIPOPHILIC DEXTRAN GEL [J].
BIZZOZERO, O ;
BESIOMORENO, M ;
PASQUINI, JM ;
SOTO, EF ;
GOMEZ, CJ .
JOURNAL OF CHROMATOGRAPHY, 1982, 227 (01) :33-44
[5]   Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis [J].
Correale, J ;
Gilmore, W ;
Lopez, J ;
Li, SQ ;
McMillan, M ;
Weiner, LP .
NATURE MEDICINE, 1996, 2 (12) :1354-1360
[6]  
FOLCH J, 1957, J BIOL CHEM, V226, P497
[7]   Specific immunotherapy: One size does not fit all [J].
Genain, CP ;
Zamvil, SS .
NATURE MEDICINE, 2000, 6 (10) :1098-1100
[8]   A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis [J].
Groux, H ;
OGarra, A ;
Bigler, M ;
Rouleau, M ;
Antonenko, S ;
deVries, JE ;
Roncarolo, MG .
NATURE, 1997, 389 (6652) :737-742
[9]   Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial [J].
Kappos, L ;
Comi, G ;
Panitch, H ;
Oger, J ;
Antel, J ;
Conlon, P ;
Steinman, L .
NATURE MEDICINE, 2000, 6 (10) :1176-1182
[10]  
Kawczak JA, 1998, J NEUROSCI RES, V54, P364, DOI 10.1002/(SICI)1097-4547(19981101)54:3<364::AID-JNR7>3.0.CO